CClinicalTrials.gg
CompletedNCT03288246Updated Jul 29, 2020

Point-of-care Viral Load Testing Among HIV-infected Adolescents in Haiti

An interventional study of point-of-care viral load test in HIV, sponsored by Weill Medical College of Cornell University. Completed at 1 site in Haiti. Open to participants aged 10 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-29.

Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
10 Years to 24 Years
Sex
All
01

Study summary

This study is designed as an individual randomized trial among 150 HIV-infected adolescents aged 10-24 years who have been on ART for >6 months and will be randomized in a 1:1 fashion to one of two arms: 1) the intervention arm (POC) will receive a POC VL test with adherence counseling informed by the VL result the same day as testing vs. 2) the standard-of-care arm (SOC) will receive a standard laboratory-based test with adherence counseling informed by the VL result 1 month later. The study tests an intervention, POC VL testing, which reduces the time between sample collection and participant receipt of results, thus decreasing the number of steps in the HIV treatment cascade. This intervention was developed to addresses health systems-based barriers which delay clinic, laboratory, and data management processes for VL monitoring for HIV-infected adolescents. Our results will contribute to research on whether POC VL testing is a feasible testing method which could be incorporated into health systems in similar resource-limited settings and whether it can improve outcomes among HIV-infected adolescents.

Read the detailed description

This study is designed as an individual randomized trial among 150 HIV-infected adolescents aged 10-24 years who have been on ART for >6 months and will be randomized in a 1:1 fashion to one of two arms: 1) the intervention arm (POC) - receiving a POC VL test with adherence counseling informed by the VL result the same day as testing vs. 2) the standard-of-care arm (SOC) - receiving a standard laboratory-based test with adherence counseling informed by the VL result 1 month later. The study tests an intervention, POC VL testing, which reduces the time between sample collection and participant receipt of results, thus decreasing the number of steps in the HIV treatment cascade. This intervention was developed to addresses health systems-based barriers which delay clinic, laboratory, and data management processes for VL monitoring for HIV-infected adolescents. The results will contribute to research on whether POC VL testing is a feasible testing method which could be incorporated into health systems in similar resource-limited settings and whether it can improve outcomes among HIV-infected adolescents. The two study arms are described below.

Standard-of-care (SOC): At the first visit after enrollment and randomization, participants in the SOC arm receive a standard laboratory-based VL test. Steps in the standard laboratory-based VL testing process include: sample collection at a phlebotomy clinic adjacent to the adolescent HIV clinic, labeling and daily storage, transportation (1 hr drive) to the central laboratory, arrival and intake at the laboratory, processing in the fully automated Abbott system, manual entry of the printed results into an excel spreadsheet by laboratory staff, and manual entry of results on the spreadsheet into the EMR by data management staff. This process - from sample collection to patient return of results - varies depending on the volume of samples collected each day and on laboratory and data management staffing. Average time from blood collection to availability of the result in the EMR is 2-3 weeks. Per standard clinical care at the adolescent HIV clinic, adolescents return for monthly visits, and the patient receives the VL result and adherence counseling which is informed by the VL result 1 month after providing the blood sample. The primary endpoint is return of the VL result within 6 weeks of sample collection to allow for a short time buffer for appointments that are not scheduled exactly 1 month from the previous visit for reasons related to school, work, family obligations, or holidays.

These standard laboratory procedures were developed to meet the high demand for VL testing when the Haitian national guidelines switched from recommending routine CD4 testing to routine VL testing. Since the Abbott systems are fully automated and can batch large quantities of samples together, this approach is appropriate for a routine nation-wide health system testing protocol. However, the need for transportation, cold-chain storage, and manual entry of thousands of results every year may not be the optimal structure for HIV-infected adolescents who are more likely to have high VL results and are more likely to be lost from care in between visits. This study will test the POC VL test vs. this standard laboratory-based test to determine if reducing the time between sample collection and patient receipt of results (removing a step in the HIV treatment cascade), can increase the impact of VL testing on clinical management and adolescent patient outcomes. The study will test if implementation of the POC VL test, in collaboration with clinicians and laboratory staff, and accompanied by patient education, can address many of the logistical barriers to laboratory-based VL testing in a resource-limited setting such as Haiti.

02

Conditions studied

  • HIV

Keywords

  • adolescent
  • HIV
  • point-of-care
  • viral load
03

Who can participate

Ages eligible
10 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Aged 10-24 years
  • HIV-infected
  • On ART for > 6 months
  • Permanent residence in Port-au-Prince
  • Able to provide informed consent/assent

Exclusion criteria

Exclusion Criteria:

  • Requires urgent VL test the day of enrollment/randomization
  • Requires ART regimen change
  • Currently pregnant
  • Co-infected with tuberculosis
  • Severe co-morbidities including cognitive impairment, bipolar disorder, psychosis, or current need for inpatient psychiatric hospitalization
04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • No intervention
    Standard-of-care

    Participants in the standard-of-care arm will receive a standard laboratory-based viral load test at baseline, 3, and 6 months.

  • Experimental
    Point-of-care

    Participants in the point-of-care arm will receive a point-of-care viral load test at baseline, 3, and 6 months.

    Diagnostic Test: point-of-care viral load test

Interventions

  • Diagnostic testpoint-of-care viral load test

    A point-of-care viral load test returns viral load test results within 90 minutes.

05

What researchers measure

Primary outcomes

  1. The number of steps in the HIV care cascade involved with viral load testing.

    The number of steps within the HIV care cascade involved with viral load testing will be measured comparing standard laboratory-based testing to POC testing.

    Time frame: 1 day of clinic visit

Secondary outcomes

  1. The proportion of participants who demonstrate comprehension of the correlation between ART adherence and viral level

    The proportion of participants who demonstrate comprehension of the correlation between ART adherence and viral level 1 month after receiving their VL test result will be measured.

    Time frame: 1 month

  2. The proportion of participants who achieve or sustain a viral level <1000 cells/ml

    The proportion of participants who achieve or sustain a viral level \<1000 cells/ml 6 months from the index VL test will be measured.

    Time frame: 6 months

06

Study locations

1 site
  • GHESKIO
    Port-au-Prince, Haiti
07

References and documents

Publications

  • Reif LK, Belizaire ME, Rouzier V, Seo G, Severe P, Bajo Joseph JM, Joseph B, Apollon S, Pape JW, McNairy ML, Elul B, Fitzgerald DW, Arpadi SM, Abrams EJ, Kuhn L. Point-of-care viral load testing among adolescents and young adults living with HIV in Haiti: a randomized control trial. AIDS Care. 2022 Apr;34(4):409-420. doi: 10.1080/09540121.2021.1981816. Epub 2021 Oct 6. PubMed 34612092 ↗
  • Reif LK, Belizaire ME, Seo G, Rouzier V, Severe P, Joseph JM, Joseph B, Apollon S, Abrams EJ, Arpadi SM, Elul B, Pape JW, McNairy ML, Fitzgerald DW, Kuhn L. Point-of-care viral load testing among adolescents and youth living with HIV in Haiti: a protocol for a randomised trial to evaluate implementation and effect. BMJ Open. 2020 Aug 31;10(8):e036147. doi: 10.1136/bmjopen-2019-036147. PubMed 32868354 ↗

Individual participant data

Plan to share: Yes — Data will be shared once the trial is complete

08

Registry details

Key details

Study ID
NCT03288246
Lead sponsor
Weill Medical College of Cornell University
Collaborators
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
Responsible party
Sponsor
First posted
Sep 20, 2017
Start date
May 3, 2018
Primary completion
Jan 30, 2020
Completion
Jan 30, 2020
Last update
Jul 29, 2020

Study contacts

Daniel Fitzgerald, MD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion